Newsletter
Subcutaneous Tirzepatide for Type 2 Diabetes, Noninvasive Respiratory Strategies for COVID-19 and Acute Hypoxemic Respiratory Failure, Clinical Outcomes 1 Year After ICU Treatment for COVID-19, and more

JAMA Editor’s Summary

Subcutaneous Tirzepatide for Type 2 Diabetes, Noninvasive Respiratory Strategies for COVID-19 and Acute Hypoxemic Respiratory Failure, Clinical Outcomes 1 Year After ICU Treatment for COVID-19, and more

Editor's Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the issue.
February 8, 2022

Subcutaneous Tirzepatide for Type 2 Diabetes, Noninvasive Respiratory Strategies for COVID-19 and Acute Hypoxemic Respiratory Failure, Clinical Outcomes 1 Year After ICU Treatment for COVID-19, and more

Editor’s Summary by Gregory Curfman, MD, Deputy Editor of JAMA, the Journal of the American Medical Association, for the February 8, 2022 issue.

Listen on your favorite player

New to Podcasts? It's easy to get started!

You may also like

The Latest Health Podcasts. Delivered to Your Inbox.

Join Our Newsletter

We gratefully acknowledge the many organizations that have generously supported our podcasts and platform.

Network Sponsors and Advertisers

Event and Media Partners

Buffer LinkedIn WhatsApp